

Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: the CLINMIR Pilot Study

Bricia López-Plaza^{1,2*}, Ana Isabel Álvarez-Mercado^{3,4,5}, Lucía Arcos-Castellanos¹, Julio Plaza-Díaz^{4,6,7}, Francisco Javier Ruiz-Ojeda^{4,5,6,8}, Marco Brandimonte-Hernández^{5,6}, Jaime Feliú-Batlle^{9,10,11}, Thomas Hummel¹², Ángel Gil^{4,5,6,8,†} and Samara Palma Milla^{1,11,13,†}

¹ Food, Nutrition and Health Platform, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain; bricia.plaza@idipaz.es; lucia.arcos.castellanos@idipaz.es

² Medicine Department, Faculty of Medicine, Complutense University of Madrid, Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain

³ Department of Pharmacology, University of Granada, 18071 Granada, Spain; alvarezmercado@ugr.es

⁴ Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitalario Universitario de Granada, 18014 Granada, Spain

⁵ Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research, University of Granada, Avda. del Conocimiento s/n, Armilla, 18016 Granada, Spain

⁶ Department of Biochemistry and Molecular Biology II, University of Granada, 18071 Granada, Spain; jrplaza@ugr.es; agil@ugr.es

⁷ Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada

⁸ CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain

⁹ Oncology Department, Hospital La Paz Institute for Health Research—IdiPAZ, Hospital Universitario La Paz, 28029 Madrid, Spain; jaime.feliu@salud.madrid.org

¹⁰ CIBERONC (CIBER Cancer), Instituto de Salud Carlos III, 28029 Madrid, Spain

¹¹ Medicine Department, Faculty of Medicine, Autonomous University of Madrid, Arzobispo Morcillo 4, 28029 Madrid, Spain

¹² Smell & Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany; thomas.hummel@tu-dresden.de

¹³ Nutrition Department, Hospital University La Paz, 28046 Madrid, Spain; samara.palma@salud.madrid.org

* Correspondence: briciaplaza@idipaz.es; Tel.: +34 917277000 Ext 449507 (B.L.-P).

† These authors contributed equally to this work.

Table S1. Perception of food consumption depending on treatment

		Standard dose of DMB			High dose of DMB			Placebo			P-value		
		1 month	2 months	3 months	1 month	2 months	3 months	1 month	2 months	3 months	1 month	2 months	3 months
Eat the same	Yes (%)	66.7	85.7	50	85.7	50	25	50	50	50	0.348	0.298	0.683
	No (%)	33.3	14.3	50	14.3	50	75	50	50	50			
Eat less	Yes (%)	22.2	0	0	0	33.3	50	0	0	0	0.204	0.089	0.032
	No (%)	77.8	100	100,00	100	66.7	50	100	100	100			
Eat more	Yes (%)	11.1	14.3	50,00	14.3	16.7	25	50	50	50	0.172	0.280	0.683
	No (%)	88.9	85.7	50,00	85.7	83.3	75	50	50	50			

Table S2. Nutritional status depending on treatment (%)

		Standard dose of DMB		High dose of DMB		Placebo		p-value	
		Baseline	3 months	Baseline	3 months	Baseline	3 months	Baseline	3 months
Weight lost percentage	No	0	87.5	0	83.3	0	100	0.772	0.556
	5 – 10	70	12.5	81.8	16.7	70	0		
	>10	30	0	18.2	0	30	0		
GLIM Criteria Malnutrition	Normal	0	62.5	0	83.3	0	71.4	0.556	0.407
	Moderate	50	12.5	81.8	16.7	70	28.6		
	Severe	50	25	18.2	0	30	0		

Table S3. Perceived effectiveness of the product depending on treatment (mean \pm SD)

	Points	Standard dose of DMB				High dose of DMB				Placebo				P-value		
		Baseline	1 week	2 months	3 months	Baseline	1 week	2 meses	3 meses	Baseline	1 week	2 meses	3 meses	Time (t)	Treatment (T)	T x t
Perceived effectiveness		33.0 \pm 27.5	33.0 \pm 27.5	62.5 \pm 23.8	63.8 \pm 21.3	46.5 \pm 25.5	44.5 \pm 27.2	71.7 \pm 24.2	58.3 \pm 37.2	66.4 \pm 42.9	59.3 \pm 40.5	75.0 \pm 38.9	75.0 \pm 38.9	0.052	0.074	0.628

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Table S4. Adverse events depending on the assigned treatment group (%)

		Standard dose of DMB			High dose of DMB			Placebo			P-value		
		1 month	2 months	3 months	1 month	2 months	3 months	1 month	2 months	3 months	1 month	2 months	3 months
Abdominal distension	Grade 0	90	87.5	100	85.7	66.7	60	100	83.3	83.3	0.649	0.629	0.157
	Grade 1	10	12.5	0	14.3	16.7	40	0	16.7	16.7			
	Grade 2	0	0	0	0	16.7	0	0	0	0			
Abdominal pain	Grade 0	90	100	87.5	85.7	100	60	83.3	100	83.3	0.578	1	0.520
	Grade 1	10	0	12.5	14.3	0	20	16.7	0	16.7			
	Grade 2	0	0	0	0	0	20	0	0	0			
Nausea	Grade 0	90	100	87.5	85.7	83.3	80	100	100	100	0.454	0.293	0.545
	Grade 1	10	0	12.5	14.3	16.7	20	0	0	0			
	Grade 2	0	0	0	0	0	0	0	0	0			
Regurgitation	Grade 0	90	100	75	85.7	100	60	100	83.3	100	0.454	0.293	0.307
	Grade 1	10	0	25	14.3	0	20	0	16.7	0			
	Grade 2	0	0	0	0	0	20	0	0	0			
Vomiting	Grade 0	100	100	100	85.7	83.3	80	83.3	100	100	0.426	0.293	0.228
	Grade 1	0	0	0	14.3	16.7	20	16.7	0	0			
	Grade 2	0	0	0	0	0	0	0	0	0			
Constipation	Grade 0	90	100	87.5	83.3	66.7	40	100	100	66.7	0.598	0.075	0.301
	Grade 1	10	0	12.5	16.7	33.3	40	0	0	33.3			
	Grade 2	0	0	0	0	0	20	0	0	0			
Diarrhea	Grade 0	100	100	100	57.1	100	60	100	100	83.3	0.019	1	0.157
	Grade 1	0	0	0	42.9	0	40	0	0	16.7			
	Grade 2	0	0	0	0	0	0	0	0	0			
Flatulence	Grade 0	70	87.5	75	85.7	50	40	100	100	83.3	0.158	0.227	0.378
	Grade 1	30	12.5	25	14.3	33.3	40	0	0	16.7			
	Grade 2	0	0	0	0	16.7	20	0	0	0			
Intensity	Grade 0	28.6	100	50	40	33.3	50	57.1	83.3	100	0.346	0.096	0.247
	Grade 1	14.3	0	50	20	0	50	42.9	16.7	0			
	Grade 2	57.1	0	0	40	66.7	0	0	0	0			
Product relationship	Grade 0	33.3	100	100	100	100	100	85.7	100	100	0.118	1	1
	Grade 1	50	0	0	0	0	0	14.3	0	0			
	Grade 2	16.7	0	0	0	0	0	0	0	0			
Conduct adopted	Grade 0	33.3	0	0	50	0	0	33.3	0	0	0.833	0.135	1
	Grade 1	50	100	100	50	0	100	66.7	100	100			
	Grade 2	16.7	0	0	0	100	0	0	0	0			

Grade 0, not described; Grade 1, mild; Grade 2, moderate.